Titan Bio Tech Ltd Stock Price Today (NSE: TITANBIO)

Titan Bio Tech Ltd

457.80+1.20 (+0.26%)
Market Closed

Fundamental Score

...

Titan Bio Tech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Titan Bio Tech Ltd share price today is 457.80, up +0.26% on NSE/BSE as of 19 June 2026. Titan Bio Tech Ltd (TITANBIO) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of 820.38 (Cr). The 52-week high for TITANBIO share price is 1460.00 and the 52-week low is 202.05. At a P/E ratio of 35.58x, TITANBIO is currently trading above its industry average P/E of 29.20x. The company has a Return on Equity (ROE) of 15.01% and a debt-to-equity ratio of 0.05.

Titan Bio Tech Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
514.00
Low
406.00
Volume
39.4K
Change
-3.39%

Titan Bio Tech Ltd share price chart: -3.39% return over the past month. 52-week high ₹1460.00, 52-week low ₹202.05.

Titan Bio Tech Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
457.75469.00442.60457.8027.77K (Cr)
454.00463.30440.40456.6038.50K (Cr)
442.95457.95440.00441.2525.34K (Cr)
449.05473.40445.80451.9530.65K (Cr)
482.00484.40450.00462.6052.19K (Cr)
472.55472.55468.00472.5528.00K (Cr)
450.05450.05438.00450.0515.57K (Cr)
414.90428.65414.90428.6518.17K (Cr)
422.50422.50406.00408.2534.95K (Cr)
436.85436.85417.00419.1028.48K (Cr)

Titan Bio Tech Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
454.00469.00440.40457.80+0.84%
495.00514.00406.00441.25-10.86%
461.00555.65392.30496.00+7.59%
202.05457.90202.05457.70+126.53%
998.801460.00238.30241.80-75.79%
1069.001132.35910.00931.25-12.89%
1028.401259.30857.001053.80+2.47%
1033.151074.00885.90979.50-5.19%
962.001419.00916.801054.20+9.58%
763.351017.00650.59948.30+24.23%
425.10748.08411.55721.94+69.83%
408.80470.00400.70427.05+4.46%

AI Research Briefing

Powered by Gemini · 2026-04-10

Overvalued micro-cap specialty chemical company with high momentum but significant downside risk if growth falters.

Research Confidence
5.0/10Moderate
MICRO-CAP DARK HORSEBreakout - CMP is -70.4% from 52W high, 3M: 45.96%, 6M: 133.09%Expensive - P/E of 35.58x vs industry P/E of 29.2x

WHAT'S HAPPENING NOW (last 2-4 weeks)

Titan Biotech hit a 52-week high of on April 7, 2026. The company's stock has shown strong momentum, trading above all key moving averages. In the latest quarter ending December 2025, Titan Biotech reported its highest quarterly net sales of s and a PBT (excluding other income) peak of s. PBDIT also reached a record s.

CORE STORY (THE REAL GAME)

Titan Bio Tech is being priced as a high-growth specialty chemicals play, leveraging both domestic demand and export opportunities. The market narrative is focused on its ability to sustain high growth rates and maintain operational efficiency.

Why Now
  • Strong quarterly results with record net sales of ₹56.51 crores
  • Stock price at 52-week high of ₹555.65
  • Bullish technical indicators (MACD, Bollinger Bands, KST)
Potential Catalysts
  • New order wins or contract announcements
  • Better-than-expected earnings in upcoming quarters
  • Expansion into new markets or product lines
Key Risks
  • Micro-cap status introduces liquidity risk
  • High P/E ratio of 35.58x compared to industry P/E of 29.2x
  • Potential for rising costs in the specialty chemicals sector
Institutional Activity

Promoter holding decreased slightly by 0.1%

Macro Context

Indian chemical production is projected to increase by 10.9% in 2026, driven by robust domestic demand and government support.

Cash Flow Quality

Profit converting to cash - Free Cash Flow 5Y: ₹54.58 Cr

3–6 Month Outlook

Expect continued growth in the specialty chemicals sector, but Titan Biotech's high valuation leaves little room for error. Monitor earnings closely and be prepared for volatility.

Primary Thesis Risk

Overvaluation and liquidity risk make this a dangerous game at these levels.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Average

Return on Equity (ROE)

15.01%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

16.90%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

22.83%

Average operating profit margin over 5 years

Dividend Yield

0.20%

Annual dividend as % of current share price

Titan Bio Tech Ltd Valuation Check

Poor

Price to Earnings (P/E)

35.58x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

29.20x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

55.78%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.03%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Average

Profit Growth (Quarterly YoY)

15.82%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

36.25%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

14.52%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

26.47%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

26.47%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.05x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

43.26x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

54.58 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Titan Bio Tech Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of TITANBIO across key market metrics for learning purposes.

Positive Indicators

12 factors identified

Strong Return on Equity (15.01%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (16.90%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (22.83%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Strong Revenue Growth (36.25%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (14.52% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (26.47% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (26.47% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.05)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (43.26x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹54.58 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (55.78%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 0.03%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Titan Bio Tech Ltd vs Specialty Chemicals Peers

Peer Comparison - Specialty Chemicals

Compare Titan Bio Tech Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
61.09999999999999/100
458
₹820.38
35.6
Average
15.01%
Good
16.90%
Good
0.1
Excellent
26.47%
Excellent
14.52%
Good
0.20%
60.4/100
1481
₹149466.57
66.6
Average
23.05%
Excellent
29.84%
Excellent
0.1
Excellent
12.63%
Good
12.49%
Good
0.68%
51.5/100
3682
₹37241.99
54.8
Average
8.29%
Poor
9.89%
Poor
0.2
Excellent
21.05%
Excellent
12.69%
Good
0.09%
40.6/100
7245
₹29462.02
66.3
Average
11.52%
Average
11.68%
Average
0.3
Excellent
-6.59%
Poor
17.22%
Excellent
0.21%
40.2/100
1715
₹21083.64
39.7
Average
13.36%
Average
16.28%
Good
0.2
Excellent
2.02%
Average
14.38%
Good
0.49%
52/100
3430
₹17807.40
46.3
Average
13.73%
Average
18.02%
Good
0.0
Excellent
57.98%
Excellent
14.83%
Good
0.49%
Atul Ltd...
ATUL500027
50.5/100
7003
₹17066.13
31.5
Average
9.10%
Poor
12.81%
Average
0.0
Excellent
-5.82%
Poor
6.41%
Good
0.43%
57.2/100
1325
₹16256.72
35.0
Average
15.75%
Good
20.61%
Excellent
0.0
Excellent
4.46%
Average
16.92%
Excellent
0.48%
37.5/100
1368
₹14036.52
92.8
Average
3.32%
Poor
7.33%
Poor
0.4
Excellent
11.97%
Good
22.13%
Excellent
0.06%
41.9/100
501
₹13796.68
51.3
Average
6.03%
Poor
6.32%
Poor
0.7
Good
-9.09%
Poor
11.68%
Good
0.26%
60.5/100
4677
₹13359.76
33.4
Average
19.47%
Good
26.39%
Excellent
0.0
Excellent
20.04%
Excellent
16.93%
Excellent
0.25%

Titan Bio Tech Ltd PE Ratio History

Historical price-to-earnings ratio for TITANBIO — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202430.07₹732.7524.4x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Titan Bio Tech Ltd Dividend History

Annual cash dividends paid by TITANBIO — dividend yield 0.20%

Financial YearDividends Paid (₹ Cr)
FY 20251.65 Cr
FY 20241.49 Cr
FY 20231.24 Cr
FY 20221.24 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Titan Bio Tech Ltd Quarterly Performance

Latest quarterly metrics for TITANBIO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

36.25%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

15.82%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

14.52%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

26.47%

Compounded annual net profit growth over 5 years

Titan Bio Tech Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for TITANBIO — calculated from daily price history

45RSI 14
Neutral — RSI 45

Momentum is balanced — neither overbought nor oversold.

SMA 50
448
▲ Price above SMA 50 — Short-term bullish
SMA 200
772
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
48K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Titan Bio Tech Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Titan Bio Tech Ltd (TITANBIO) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Titan Bio Tech Ltd

About TITANBIO (Titan Bio Tech Ltd)

Titan Bio Tech Ltd is a pioneering force in the specialty chemicals sector, dedicated to the research, development, and production of innovative biological solutions. Focusing on c...utting-edge bio-processing techniques, TITANBIO creates high-performance chemical components for a wide array of industrial applications. The company emphasizes sustainable practices throughout its manufacturing processes, striving to minimize environmental impact while maximizing product efficacy. Through strategic partnerships and a commitment to technological advancement, TITANBIO seeks to remain at the forefront of the industry, anticipating and meeting the evolving needs of its diverse clientele. The company places a strong emphasis on quality control, ensuring that every product meets rigorous standards for purity, potency, and safety. TITANBIO distinguishes itself by offering a comprehensive portfolio of specialty chemicals tailored to enhance product performance and sustainability. Their extensive range of offerings includes advanced protein derivatives, fermentation-derived ingredients, and other bio-active compounds. These specialized chemicals find application in various sectors, including food and beverage, cosmetics, pharmaceuticals, and animal nutrition. TITANBIO prides itself on its ability to customize solutions to meet specific customer requirements, leveraging its expertise in bio-chemistry and chemical engineering. The company's R&D team is constantly exploring new avenues for innovation, developing novel solutions that address emerging market trends and environmental challenges. The product's applications range from enriching animal feed formulations, creating advanced bio-fertilizers, or enabling sustainable cosmetic development. TITANBIO is committed to global outreach, with a growing presence in both established and emerging markets. The company prioritizes building strong, long-term relationships with its customers, providing technical support and expert guidance to ensure optimal product utilization. Through active participation in industry events and research collaborations, TITANBIO aims to foster knowledge sharing and drive innovation within the specialty chemicals community. Their commitment to excellence extends beyond product quality to encompass customer service, environmental responsibility, and ethical business practices. TITANBIO aspires to be a trusted partner for businesses seeking sustainable and high-performance chemical solutions, contributing to a more environmentally friendly and technologically advanced future. The company's emphasis on regulatory compliance and safety ensures that its products meet the highest global standards.

Company Details

Symbol:TITANBIO
Industry:Specialty Chemicals
Sector:Specialty Chemicals

Key Leadership

Mr. Naresh Kumar Singla
MD & Executive Director
Mr. Suresh Chand Singla
MD & Executive Director
Mr. Prem Shankar Gupta
Chief Financial Officer

Corporate Events

Recent
Ex-Dividend Date

TITANBIO Share Price: Frequently Asked Questions

What is the current share price of Titan Bio Tech Ltd?

Titan Bio Tech Ltd (TITANBIO) trades at ₹457.80 on NSE and BSE. Market cap ₹820.38 (Cr). Educational data only.

What is the P/E ratio of Titan Bio Tech Ltd?

Titan Bio Tech Ltd has a P/E of 35.58x vs industry average 29.20x.

What is the Bull Run score for Titan Bio Tech Ltd?

Titan Bio Tech Ltd has a Bull Run score of 61.09999999999999/100 based on 25+ financial parameters.

Does Titan Bio Tech Ltd pay dividends?

Titan Bio Tech Ltd has a dividend yield of 0.20%. Past dividends don't guarantee future payments.

What is the ROE of Titan Bio Tech Ltd?

Titan Bio Tech Ltd has ROE of 15.01%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Titan Bio Tech Ltd?

Titan Bio Tech Ltd has debt-to-equity of 0.05.

Is Titan Bio Tech Ltd a good investment?

Bull Run gives Titan Bio Tech Ltd a score of 61.09999999999999/100. This is not investment advice — consult a SEBI-registered advisor.